Cybin reports third quarter financial results and recent business highlights

Toronto--(business wire)--cybin inc. (nyse american:cybn) (cboe ca:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, today reported unaudited financial results for its third quarter ended december 31, 2023, and recent business highlights. “during the past three months, we have continued to make exciting progress with positive topline data from.
CYBN Ratings Summary
CYBN Quant Ranking